Regulation of circulating sclerostin levels by sex steroids in women and in men

Journal of Bone and Mineral Research

Volumn 26, Issue 1, 2011, Pages 27-34

  Mödder, Ulrike Il ^a   Clowes, Jackie A ^a   Hoey, Kelley ^a   Peterson, James M ^a   McCready, Louise ^a   Oursler, Merry Jo ^a   Riggs, B Lawrence ^a   Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

Author keywords

BONE TURNOVER; ESTROGEN; SCLEROSTIN; TESTOSTERONE

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ESTROGEN; SCLEROSTIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HUMAN; MALE; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; COLLAGEN TYPE I; ESTRADIOL; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PEPTIDES; TESTOSTERONE;

EID: 78650955673     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.128     Document Type: Article

References (38)

1. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992; 117: 1-9.
2. Riggs BL, Khosla S, Melton LJ., Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002; 23: 279-302.
3. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC., Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. J Clin Invest. 1998; 101: 1942-1950.
4. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL., Effect of blockade of TNF-α and interleukin 1 action on bone resorption in early postmenopausal women. J Bone Miner Res. 2007; 22: 724-729.
5. Hannon R, Blumsohn A, Naylor K, Eastell R., Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998; 13: 1124-1133.
6. Lean JM, Chow JW, Chambers TJ., The rate of cancellous bone formation falls immediately after ovariectomy in the rat. J Endocrinol. 1994; 142: 119-125.
7. Manolagas SC., Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21: 115-137.
8. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S., Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000; 106: 1553-1560.
9. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS., Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003; 88: 204-210.
10. Sanyal A, Hoey KA, Modder UI, et al. Regulation of bone turnover by sex steroids in men. J Bone Miner Res. 2008; 23: 705-714.
11. Baron R, Rawadi G., Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635-2643.
12. Krishnan V, Bryant HU, MacDougald OA., Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116: 1202-1209.
13. Armstrong VJ, Muzylak M, Sunters A, et al. WNT/B-Catenin signaling is a component of osteoblastic bone cells' early responses to load-bearing, and requires estrogen receptor a. J Biol Chem. 2007; 282: 20715-20727.
14. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-589.
15. Balemans W, Ebeling M, Patel N, et al. Increase bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-543.
16. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144-152.
17. Balemans W, Patel N, Ebeling M, et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91-97.
18. Li X, Ominsky MS, Niu Q-T, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860-869.
19. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578-588.
20. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA., Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95: 1991-1997.
21. Clowes JA, Eghbali-Fatourechi GZ, McCready L, Oursler MJ, Khosla S, Riggs BL., Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int. 2009; 20: 761-769.
22. Terpos E, Christoulas D, Katodritou E, et al. High serum sclerostin correlates with advanced stage, increased bone resorption, reducted osteoblast function, and poor survival in newly-diagnosed patients with multiple myeloma. Blood. 2009; 114: (ASH Annual Meeting):Abstract 425
23. Glass DA II, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-764.
24. Huang Q-Y, Li GHY, Kung AWC., The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone. 2009; 45: 289-294.
25. Boruk M, Savory JG, Hache RJ., AF-2-dependent potentiation of CCAAT enhancer binding protein beta-mediated transcriptional activation by glucocorticoid receptor. Mol Endocrinol. 1998; 12: 1749-1763.
26. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V., Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005; 102: 11651-11656.
27. Carroll JS, Liu S, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005; 122: 33-43.
28. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994; 331: 1056-1061.
29. Smith EP, Specker B, Bachrach BE, et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab. 2008; 93: 3088-3096.
30. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997; 337: 91-95.
31. Bilezikian JP, Morishima A, Bell J, Grumbach MM., Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 1998; 339: 599-603.
32. Syed F, Khosla S., Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005; 328: 688-696.
33. Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010; 95: 5056-5062.
34. Padhi D, Stouch B, Jang G, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. American Society for Bone and Mineral Research Annual Meeting. 2007; (Abstract 1129).
35. Kearns AE, Khosla S, Kostenuik PJ., Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008; 29: 155-192.
36. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG., Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006; 119: 1283-1296.
37. Modarresi R, Xiang Z, Yin M, Laurence J., WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol. 2009; 174: 123-135.
38. Qiang Y-W, Chen Y, Brown N, et al. Characterization of Wnt/beta-catenin signaling in osteoclasts in multiple myeloma. Br J Haematol. 2009; 148: 726-738.